[New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
New vitamin D derivatives were introduced to clinical use for the treatment of secondary hyperparathyroidism. Patients who were treated by paricalcitol survived more than patients who were treated by calcitriol. Doxercalciferol and paricalcitriol could maintain suppressed parathyroid hormone (PTH) with less frequent hypercalcemic accidents. Cinacalcet suppressed serum PTH levels in dialysis patients and decreased serum calcium and phosphate concentrations. We must further investigate these new drugs' outcomes, by measuring mortality and morbidity.
Akiba
Takashi
T
Tokyo Women's Medical University, Department of Blood Purification, Tokyo, Japan.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D000069449:Cinacalcet; D004872:Ergocalciferols / Q000627:therapeutic use*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications; D009281:Naphthalenes / Q000627:therapeutic use*; D014807:Vitamin D / Q000031:analogs & derivatives*
D050071:Bone Density Conservation Agents; D004872:Ergocalciferols; D009281:Naphthalenes; D014807:Vitamin D; C042533:1 alpha-hydroxyergocalciferol; C084656:paricalcitol; D000069449:Cinacalcet